What is a multidisciplinary tumor board and should my HER2-Positive Breast Cancer case be presented

Understanding Multidisciplinary Tumor Boards for HER2-Positive Breast Cancer

What Is a Multidisciplinary Tumor Board?

A multidisciplinary tumor board (often called a "molecular tumor board" when focused on genetic testing) is an interdisciplinary team of experts in the disease field who meet together to review and discuss individual patient cases. These teams typically include:

• Medical oncologists (cancer specialists)
• Surgical oncologists (cancer surgeons)
• Radiation oncologists (radiation specialists)
• Pathologists (tissue specialists)
• Radiologists (imaging specialists)
• Genetic counselors (for hereditary cancer assessment)
• Nurses and other specialists relevant to your case

The goal is to combine different medical perspectives to develop the most comprehensive treatment recommendations for your specific situation.

How Tumor Boards Work for Treatment Planning

According to the Cancer Patient Lab webinars on precision oncology, tumor boards serve an important function: they help match patients with treatments by considering the totality of your medical information—not just one test result or one doctor's opinion.

However, it's important to understand a key limitation: research shows that when the same molecular diagnostic test results are sent to two different tumor boards, concordance (agreement) on treatment recommendations is only 44-63%. This means tumor boards can vary in their recommendations, which is why your active participation in understanding your case is valuable.

Should Your HER2-Positive Breast Cancer Case Be Presented?

Yes, your case is an excellent candidate for tumor board review. Here's why:

HER2-Positive Breast Cancer Is Complex

HER2-positive breast cancer (where the cancer cells have extra copies of the HER2 gene or overexpress the HER2 protein) typically benefits from targeted anti-HER2 therapies. Your case likely involves multiple treatment considerations:

• Dual anti-HER2 therapy options (such as trastuzumab/Herceptin and pertuzumab/Perjeta)
• Chemotherapy combinations paired with targeted therapy
• Hormone receptor status (whether your cancer is also ER/PR positive or triple-negative)
• Stage of disease (early-stage vs. metastatic)
• Other genetic mutations that might influence treatment choices

When Tumor Board Review Is Particularly Valuable

According to the webinar on "Matching Patients with Treatments," tumor boards are especially helpful when:

1. You have multiple biomarkers - If your testing shows HER2-positive status PLUS other mutations (like BRCA mutations, hormone receptor positivity, or other genetic alterations), a tumor board can help determine which treatment pathway is best for YOUR specific combination of findings

2. You're considering off-label or novel combinations - If your oncologist is recommending treatments beyond standard first-line options, a tumor board can provide additional expert perspective

3. You want comprehensive molecular analysis - If you've had genomic testing (DNA sequencing, RNA sequencing, or other molecular profiling), a tumor board can integrate all this information into treatment planning

Questions to Ask Your Oncologist About Tumor Board Review

To advocate for yourself effectively, consider asking:

1. "Will my case be presented to a multidisciplinary tumor board, and if so, when?"

2. "What specific information will be reviewed—just my pathology report, or will my genomic testing results also be included?"

3. "Who will be on the tumor board, and will there be a pathologist and genetic counselor involved?"

4. "How will the tumor board's recommendations be communicated to me, and will I have a chance to discuss them?"

5. "If I've had additional testing done (like comprehensive genomic profiling), will those results be included in the tumor board discussion?"

6. "Are there any clinical trials that the tumor board might recommend for my specific HER2-positive profile?"

Important Context: Tumor Boards vs. IRBs

One clarification from the webinars: a tumor board is NOT an Institutional Review Board (IRB). An IRB is specifically for protecting patients in research studies. A tumor board is a clinical tool for treatment planning. This distinction matters if you're considering clinical trial participation—those would require separate IRB oversight.

Moving Forward

Your HER2-positive breast cancer diagnosis absolutely warrants multidisciplinary tumor board review. This is standard of care for complex breast cancer cases and can help ensure you're receiving the most current, evidence-based treatment recommendations tailored to your specific tumor characteristics.

If your current oncology center doesn't routinely present cases to a tumor board, or if you want a second opinion, you can request that your case be reviewed at a comprehensive cancer center that has active tumor board programs.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.